DenovAI Biotech

We're delighted to mark our 1st birthday at DenovAI Biotech since it launched as a portfolio company of the AION Labs venture studio. AION Labs aspires to a noble vision to transform drug discovery and development for the betterment of human health. At DenovAI we share this vision – our mission is to harness the power of AI and computational biophysics to not only accelerate the pace of discovery but also galvanize the entire industry by widening its scope to tackle many challenging and unmet needs. That is what has inspired us to develop a state-of-the-art AI-physics-based protein design engine that can discover next-generation therapeutic miniprotein and antibody binders completely de novo. It's been an honour to see DenovAI grow into a fantastic team of passionate talented multidisciplinary scientists, welcome new investment partners, and develop and deploy our platform. This could not have been possible without the immense dedication of the DenovAI team, the continuous support of all those involved in our journey from the insights of our board of directors and scientific mentors, to the efforts of the AION Labs team as well as all the guidance of our partners and stakeholders in the wider AION community. So, on behalf of the entire DenovAI team, a heartfelt thanks to our entire community and looking forward to many more exciting developments to come in Year Two! AION Labs, Amiti, Israel Biotech Fund, Amazon Web Services (AWS), AstraZeneca, Merck Group, Pfizer, Teva Pharmaceuticals, BioMed X Institute, Israel Innovation Authority, EMBL, BioLabs

DenovAI Biotech congratulates David Baker, Demis Hassabis and John Jumper for winning a well-deserved Nobel Prize in Chemistry! We're delighted but by no means surprised! David Baker, at the University of Washington, pioneered computational protein design which has flourished into a revolutionary field with de novo protein design - designing new proteins completely from scratch - being at the frontier. Demis Hassabis and John Jumper, together with their team at Google DeepMind cracked one of the grand challenges in biology using their AI approach, AlphaFold2 - accurately predicting the structure of proteins from their amino acid sequences. This has enabled predicting structures of nearly every protein known to humankind. We at DenovAI Biotech together with our partners at AION Labs are privileged and honoured to be developing state-of-the-art platforms that combine computational biophysics and AI to push the de novo protein design frontier forward in our mission to accelerate the pace of drug development and to design next-generation miniprotein and antibody therapeutics. Such therapeutics could transform the lives of millions of people around the world and broaden the scope of therapy to many new challenging diseases. AION Labs, Amiti, AstraZeneca, Merck Group, Pfizer, Teva Pharmaceuticals, Israel Biotech Fund, Israel Innovation Authority, BioMed X Institute, Amazon Web Services (AWS), BioLabs

Welcome aboard Alexander! We are delighted to welcome Alexander Geller to DenovAI Biotech as a Research Scientist. Alex brings a wealth of skills in structural bioinformatics, genomics and deep learning, having recently finished his Ph.D. at the Hebrew University’s Faculty of Agriculture, and we are thrilled to have him join the team. AION Labs, AstraZeneca, Merck Group, Pfizer, Teva Pharmaceuticals, Amiti, Israel Biotech Fund, Amazon Web Services (AWS), BioMed X Institute, Israel Innovation Authority, EMBL

Welcome aboard Lavi! We are delighted to welcome Lavi Bigman to DenovAI Biotech as a Senior Research Scientist. Lavi brings a wealth of expertise in computational biophysics and machine learning and we are thrilled to have him join the team. AION Labs, AstraZeneca, Merck Group, Pfizer, Teva Pharmaceuticals, Amiti, Israel Biotech Fund, Amazon Web Services (AWS), BioMed X Institute, Israel Innovation Authority, EMBL

Welcome aboard Orly!   We are delighted to welcome Orly Marcu to DenovAI Biotech as a Senior Research Scientist. Orly brings a wealth of expertise in protein design and computational bioinformatics and we are thrilled to have her join the team. AION Labs AstraZeneca Merck Group Pfizer Teva Pharmaceuticals Amiti Israel Biotech Fund Amazon Web Services (AWS) BioMed X Institute Israel Innovation Authority EMBL

Welcome aboard Yoav!   We are delighted to welcome Yoav Atsmon Raz to DenovAI Biotech as Head of Computational Biology. Yoav brings great experience and leadership in computational structural biology and biophysics in both academia and industry, and we are excited to have him on the team. AION Labs AstraZeneca Merck Group Pfizer Teva Pharmaceuticals Amiti Israel Biotech Fund Amazon Web Services (AWS) BioMed X Institute Israel Innovation Authority

Welcome to DenovAI, Tal!   We are delighted to welcome Tal Leibovich-Rivkin to DenovAI Biotech as COO. Tal brings a wealth of industry-proven experience and talented leadership in drug discovery, and we are thrilled to have her on the team. AION Labs AstraZeneca Merck Group Pfizer Teva Pharmaceuticals Amiti Israel Biotech Fund Amazon Web Services (AWS) BioMed X Institute Israel Innovation Authority